Lyell Immunopharma, Inc. Stock-Based Compensation
Lyell Immunopharma, Inc. (LYEL) reported Stock-Based Compensation of $8.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Lyell Immunopharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $4.53M, a 9.43% decline year-over-year.
- Lyell Immunopharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $4.29M, a 28.70% decline year-over-year.
- Lyell Immunopharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $25.57M, a 216.33% increase year-over-year.
- Lyell Immunopharma, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $5.23M, a 31.36% decline year-over-year.
- Lyell Immunopharma, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $41.83M, a 26.20% increase from fiscal 2024.
- Lyell Immunopharma, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $33.14M, a 29.61% decline from fiscal 2023.
- Lyell Immunopharma, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $47.08M, a 42.53% decline from fiscal 2022.
- Lyell Immunopharma, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $81.92M, a 31.71% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $8.83M 10-Q · filed 2026-08-06 | $34.40M derived: sum of 3 quarters · filed 2026-08-06 | $39.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.29M 10-Q · filed 2026-05-06 | $29.86M derived: sum of 2 quarters · filed 2026-05-06 | $35.10M derived: sum of 3 quarters · filed 2026-05-06 | $40.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $25.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $30.80M derived: sum of 2 quarters · filed 2026-03-12 | $35.80M derived: sum of 3 quarters · filed 2026-08-06 | $41.83M 10-K · filed 2026-03-12 |
| 2025-09-30 | $5.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $10.24M derived: sum of 2 quarters · filed 2026-08-06 | $16.26M 10-Q · filed 2025-11-12 | $24.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $11.03M 10-Q · filed 2026-08-06 | $19.11M derived: sum of 3 quarters · filed 2026-08-06 | $26.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.02M 10-Q · filed 2026-05-06 | $14.11M derived: sum of 2 quarters · filed 2026-05-06 | $21.73M derived: sum of 3 quarters · filed 2026-05-06 | $30.01M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $8.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $15.71M derived: sum of 2 quarters · filed 2026-03-12 | $23.99M derived: sum of 3 quarters · filed 2026-03-12 | $33.14M 10-K · filed 2026-03-12 |
| 2024-09-30 | $7.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $15.91M derived: sum of 2 quarters · filed 2025-11-12 | $25.06M 10-Q · filed 2025-11-12 | $33.52M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $8.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $17.44M 10-Q · filed 2025-08-12 | $25.90M derived: sum of 3 quarters · filed 2026-03-12 | $36.42M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $9.15M 10-Q · filed 2025-05-13 | $17.62M derived: sum of 2 quarters · filed 2026-03-12 | $28.13M derived: sum of 3 quarters · filed 2026-03-12 | $42.36M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $8.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $18.98M derived: sum of 2 quarters · filed 2026-03-12 | $33.20M derived: sum of 3 quarters · filed 2026-03-12 | $47.08M 10-K · filed 2026-03-12 |
| 2023-09-30 | $10.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $24.74M derived: sum of 2 quarters · filed 2024-11-07 | $38.62M 10-Q · filed 2024-11-07 | $56.98M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $14.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $28.11M 10-Q · filed 2024-08-07 | $46.47M derived: sum of 3 quarters · filed 2025-03-11 | $65.59M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $13.88M 10-Q · filed 2024-05-06 | $32.24M derived: sum of 2 quarters · filed 2025-03-11 | $51.37M derived: sum of 3 quarters · filed 2025-03-11 | $73.78M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $18.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $37.49M derived: sum of 2 quarters · filed 2025-03-11 | $59.90M derived: sum of 3 quarters · filed 2025-03-11 | $81.92M 10-K · filed 2025-03-11 |
| 2022-09-30 | $19.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $41.53M derived: sum of 2 quarters · filed 2023-11-07 | $63.56M 10-Q · filed 2023-11-07 | $84.74M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $22.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $44.44M 10-Q · filed 2023-08-08 | $65.62M derived: sum of 3 quarters · filed 2024-02-28 | $78.66M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $22.03M 10-Q · filed 2023-05-04 | $43.21M derived: sum of 2 quarters · filed 2024-02-28 | $56.25M derived: sum of 3 quarters · filed 2024-02-28 | $71.50M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $21.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $34.22M derived: sum of 2 quarters · filed 2024-02-28 | $49.47M derived: sum of 3 quarters · filed 2024-02-28 | $62.20M 10-K · filed 2024-02-28 |
| 2021-09-30 | $13.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $28.29M derived: sum of 2 quarters · filed 2022-11-08 | $41.02M 10-Q · filed 2022-11-08 | $53.99M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $15.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $27.98M 10-Q · filed 2022-08-04 | $40.95M derived: sum of 3 quarters · filed 2023-02-28 | $50.70M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $12.73M 10-Q · filed 2022-05-10 | $25.70M derived: sum of 2 quarters · filed 2023-02-28 | $35.45M derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | $12.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $22.72M derived: sum of 2 quarters · filed 2023-02-28 | $33.26M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $9.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $20.29M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $10.54M 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $15.73M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |